Background: There has always been a controversy on the hepatectomy for huge hepatocellular carcinoma (HCC). Therefore, we aim to explore the hepatectomy efficacy of huge HCC and its risk factors.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common cancer in the world. [1] With the development of comprehensive therapy including locoregional and systemic treatment, HCC has not more than a lethal cancer, especially in eastern Asia. [2] Up to now, surgical resection has been considered as the most efficient therapy. [3] While, as for huge HCC (i.e., >10 cm in diameter), it is hard to say.
Firstly, huge HCC is the absolute contraindication of the liver transplantation. [4] Secondly, radiofrequency ablation (RFA) [5] and trans-arterial chemoembolization (TACE) [6] has been proved to be of little efficacy. Moreover, Sorafenib, as the only therapeutic targeted drug approved by the FDA, could not achieve tumor regression. [7] Hence, surgical resection is the only option for huge HCC.
In this meta-analysis, not only the efficacy of hepatectomy of huge HCC was evaluated, but also the safety and feasibility were assessed. And in addition, the risk factors associated with the results were also analyzed. 
Material and methods

Literature search
A comprehensive search was conducted to clarify all the published researches of hepatectomy on huge HCC versus non-huge HCC. Both English electronic databases such as PubMed, MedLine, the Cochrane Library, Web of Knowledge, and Chinese databases including Wan Fang, CNKI, and SinoMed were used to seek the literature, from September 1990 to September 2017. Keywords including "hepatocellular carcinoma " and "hepatectomy" combined with free text words such as "huge" or "giant" or "larger more than 10 cm" or "≥10 cm in diameter" appeared in the electronic search.
Selection criteria
Huge HCC was defined as the diameter of the HCC tumor exceeding 10 cm.
Inclusion criteria: cohort studies and randomized controlled trials were both considered; hepatectomy for huge HCC and non-huge HCC;
survival was analyzed in the study; sufficient data such as the baseline of characteristic were depicted.
Exclusion criteria: in vitro or animal studies; case reports, letters, reviews and conference reports; studies based on overlapping cohorts derived from the same center; sample size was not more than 10.
In case of results reported from the same center more than once, the latest was extracted.
Data extraction
All data were extracted and assessed by 2 independent investigators with predefined forms such as baseline characteristics and outcomes from each study. In the case of disagreement, a third investigator intervened for a conclusion. Hazard ratios (HRs) of overall survival (OS) and recurrence-free survival (RFS) were calculated according to Tierney' algorithm. [8] 
Intervention definition
Partial resection was divided into anatomical and nonanatomical resection according to whether complianced with anatomical structure, minor and major hepatectomy according to the size of the liver resection, and open and laparoscopic hepatectomy according to whether performed by laparoscope.
Minor hepatectomy was defined as the liver resections <3.
Major hepatectomy was defined as the liver resections no fewer than 3.
Quality assessment
Cohort studies were assessed by Newcastle-Ottawa scale (NOS), [9] and studies scored as ≥ 6 were considered high quality. [10] 
Statistical analysis
The systematic review and meta-analysis were registered at http://www.researchregistry.com and performed using RevMan Version 5.3. HR was applied as a summary statistic for time-to-event outcomes like OS and RFS, odd ratio (OR) was for the dichotomous outcomes and standard mean difference (SMD) was for the continuous outcomes, and all the results followed with 95% confidence intervals (CI). The x 2 test and I 2 statistics were used to assess the heterogeneity; P < .05 or I 2 >50% were considered as significant heterogeneity. When the hypothesis of homogeneity was not rejected, the fixedeffects model was used to estimate the case with homogeneity, and the random-effects model was used for the cases with significant heterogeneity. [10] 3. Results
Search
Initially, 324 reports were identified initially by 2 independent reviewers including both English and Chinese. A total of 18 articles were excluded after duplicate removal by NoteExpress 3.1. After browsing the titles and abstracts, 283 records were excluded. Among the remaining 13 articles, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] one record was excluded for lack of enough cases. [13] So, there were 12 reports included in this meta-analysis. [11, 12, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] In total, 7049 patients were enrolled in this meta-analysis, with 1770 cases in the huge HCC group and 5279 cases in the with non-huge HCC group ( Fig. 1) 
Trial characteristics
The characteristics and quality of the included trials are shown in Table 1 . All the 12 studies included huge HCC group and nonhuge HCC group. Follow-up was not mentioned in 1 study, and the remaining had complete follow-up (Table 1) . Except for one study, risk factors such as gender, age, preoperative AFP level, tumor characteristic and vascular invasion and so on were involved in all the 12 studies. All the studies included in this metaanalysis were nonrandomized studies and were assessed by NOS. The scores ranged from 7 to 8, indicating that all the studies were high quality (Table 1) .
Long-term outcome of hepatectomy for huge HCC and non-huge HCC
Long-term outcome of hepatectomy including OS and RFS rates were reported in the nine studies, and there were significantly differences in the rate of OS (HR = 2.18, 95% CI = 1.90-2.50, P < .00001; I 2 = 66%, P = .003. Fig. 2A ) and RFS (HR = 1.97, 95% CI = 1.76-2.19, P < .00001; I 2 = 74%, P = .0001. Fig. 2B ) between huge HCC group and non-huge HCC group. And, there were also significantly decreases in the 1-year, 3-year, and 5-year OS (75% vs 90%, P = .002; 52% vs 74%, P = .002; 40% vs 60%, P = .03; respectively) and RFS (46% vs 73%, P < .0001; 30% vs 47%, P < .00001; 20% vs 35%, P = .0002; respectively. Tables 2 and 3 ). However, the RDs were considerably small (ranged from À0.20 to À0.05, Table 3 ), which meant that the long-term outcome of hepatectomy for huge HCC was acceptable.
3.4. Short-term outcome of hepatectomy for huge HCC and non-huge HCC Short-term outcome of hepatectomy was assessed by treatmentrelated complications and hepatectmoy mortality. And, there were no significant differences in the rates of treatment-related complications (RD = 0.07, 95% CI = À0.09-0.23, P = .38; I 2 = 66%, P = .05, Fig. 3A ) and hepatectmoy mortality (RD = 0.01, 95% CI = À0.00-0.03, P = .06; I 2 = 30%, P = .22, Fig. 3B ) between huge HCC group and non-huge HCC group. AFP = alpha fetal protein, CI = confidence interval, EM = effect model, MVI = micorvascular invasion, OR = odds ratio, OS = overall survival, PVTT = portal vein tumor thrombus, RFS = recurrence-free survival or relapse-free survival, SMD = std, mean difference.
Table 2
The comparison of 1-year, 3-year, 5-year OS or RFS between huge HCC and non-huge HCC. 
Studies included
Risk factors of hepatectomy for huge HCC and non-huge HCC
Risk factors such as gender, age, tumor characteristic and so on were analyzed. Results showed that as for the hepatectomy, there were significant differences in the preoperative AFP levels (SMD = 0.57, 95% CI = 0.26-0.88, P = .0003), the rate of positive margin (OR = 32.52, 95% CI = 1.02-6.22, P = .04), the rate of worse classification (OR = 2.91, 95% CI = 1.68-5.04, P = .0001), the rate of incomplete capsule (OR = 3.99, 95% CI = 3.40-4.67, P < .00001), the rate of combined satellite nodules (OR = 2.52, 95% CI = 1.66-3.83, P < .0001), the rate of MVI (OR = 2.52, 95% CI = 1.66-3.83, P = .001), and the rate of PVTT (OR = 2.75, 95% CI = 2.29-3.31, P < .00001) between huge HCC group and non-huge HCC group (Table 3) .
Sensitivity analysis
Significant heterogeneities were observed among the included studies for OS and RFS rate. The studies conducted by Liau et al [19] and Allemann et al [14] showed results were significantly different from others, which likely contributed to the heterogeneities. After excluding these two studies, the pooled HRs for OS rate and RFS rate using the fixed-effect model were 2.47 (95% CI 2.13-2.86, P < .00001; I 2 = 18%, P = .29) and 2.21 (95% CI 1.96-2.48, P < .00001; I 2 = 0%, P = .47), respectively.
Discussion
Hepatectomy is still the most effective therapy for the huge HCC, [12] although the clinical value has always been questioned. In this meta-analysis, the feasibility and efficacy of hepatectomy for huge HCC has been demonstrated by evidence-based medicine.
It is prerequisite for the feasibility of hepatectomy. Tumor size was used to be the restriction of hepatectomy for HCC. [24] [25] [26] Hwang et al [27] found that it was resectable for huge HCC, and the rate of anatomical hepatectomy and R0 resection were 91.9% and 89.4%, respectively. Compared with the non-huge HCC, the patients of huge HCC tended to be younger epidemiologically and rarely combined with serious cirrhosis. Hence, it is absolutely feasible of hepatectmoy for huge HCC, especially for those young patients with favorable liver function.
It is essential to evaluate the efficacy of hepatectomy for huge HCC. A propensity score analysis showed that hepatectomy for large HCC (>5 cm in diameter) including huge HCC was superior to local-regional therapy. Similarly, the efficacy of hepatectomy for large HCC including huge HCC was reported to superior to TACE in the latest meta-analysis. And, exceeding two liver sections was considered to be independent prognostic factor for huge HCC. In this meta-analysis, we found that the rates of 1-year, 3-year, and 5-year OS were 75%, 52%, and 40%, which were acceptable, although they were significantly lower than those of non-huge HCC.
Safety is the key of hepatectomy for huge HCC. Severe complications did not increase after hepatectomy, compared with local-regional therapy such as TACE. [28, 29] On the other hand, the median mortality was reported to be 3.5% in a systematic review, [30] which was much lower in the latest report. [31] In this meta-analysis, there were no significant differences on the postoperative complications and mortality between huge HCC group and non-huge HCC group, which indicated that it was safe to perform hepatectomy for huge HCC.
Based on these above, huge HCC was not considered to be a contraindication for hepatectomy. However, the criteria should not be expanded unlimitedly. Both tumor characteristic such as classification, capsule, and operative variables including intraoperative estimated blood loss, [32] anatomical or non-anatomical hepatectomy [33] [34] [35] were reported to be risk factors of hepatectomy for huge HCC. Other factors including AFP dynamic changes, [36] MVI, [37] and cirrhosis [38] were also considered to affect the efficacy of hepatectomy seriously. All of the risk factors were enrolled in this meta-analysis, and results showed that in the huge HCC group, the level of preoperative AFP was higher, the rate of positive margin increased, the tumor characteristic tended to be worse including lower classification, incomplete capsule and combined satellite nodules, and the incidence of MVI and PVTT increased, too, compared with non-huge HCC. And therefore, it should be prudent for us to conduct hepatectomy for huge HCC patients accompanied with such factors. There were several limitations in this study. First, there were no RCTs included in this meta-analysis, which made the conclusion sound weaken because cohort data had selection bias. Second, survival data such as OS and DFS/RFS were extracted from survival curves, which might be brought with several tiny errors. Third, the definition of MVI varied due to the lack of a golden standard. [39] [40] [41] Fourth, measurement data and enumeration data were mixed up to record the same variable such AFP level. [11, 12, 15, 16] Fifth, the baseline characteristics varied from each other, caution should be taken when interpreting these results. Finally, it was hard to avoid publication bias, because the journals tend to publish positive results.
Conclusion
In summary, we concluded that hepatectomy for huge HCC was feasible and effective in this meta-analysis. And, the survival will be improved in the future with the advent of precision hepatectomy, administration of newly targeted drugs and combination with systematic therapy. However, hepatectomy is not suitable for all the huge HCC patients, criteria should be worked out in future, and related risk factors should be taken into consideration.
